Latest / Stock Movers / Gilead Slips on Arcellx Acquisition; Merck Rallies; Domino's Rises
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market. Harnessing the power of Bloomberg Data.
- 0:16Speaker 1: Let's take a look at some stocks on the move today.
- 0:18Speaker 1: I'm Nathan Hager, joined by Bloomberg's Dan Curtis on a
- 0:21Speaker 1: morning with a lot going on in the pharma space,
- 0:25Speaker 1: including the latest in the obesity drug wars, another setback
- 0:30Speaker 1: for Nova nordis. Good morning Dan, Good morning Nathan.
- 0:34Speaker 3: That's right. I'm not sure what's falling harder this morning.
- 0:36Speaker 3: Novo notice shares or the snow but ticker Envo for
- 0:40Speaker 3: the usadrs. Those shares are down fifteen percent as the
- 0:43Speaker 3: pharmaceuticals next gen obcit shot Kagrissima, is less effective than
- 0:48Speaker 3: Eli Lilly's rival in a trial. So this morning Novo
- 0:51Speaker 3: came out saying that in its trial there is twenty
- 0:55Speaker 3: percent weight loss after about a year and a half.
- 0:57Speaker 3: That's versus nearly twenty four percent weight loss from Eli Lily.
- 1:02Speaker 3: Kigrosima is a key piece for novo strategy that's ahead
- 1:05Speaker 3: of the patent xpree for its headline with go vi
- 1:08Speaker 3: ozembic weight loss drugs and the Wall Straight Street base
- 1:11Speaker 3: case going into this is that Novo's drug wouldn't be
- 1:14Speaker 3: worse than Eli Lilly. That's according to a UBS note.
- 1:17Speaker 3: So this taking markets off guard, those shares down fifteen percent,
- 1:21Speaker 3: Eli Lilly the competitor, getting a three percent pop in
- 1:24Speaker 3: pre market.
- 1:25Speaker 1: And we have some deal news in the pharma space.
- 1:27Speaker 1: Gilead Sciences on the hunt this morning.
- 1:31Speaker 3: That's right, Gilead has announced it's going to buy Our
- 1:33Speaker 3: Selects for one hundred and fifteen dollars in cash plus
- 1:36Speaker 3: a contingent value right of five dollars a share, so
- 1:39Speaker 3: up to one hundred and twenty dollars a share. That's
- 1:41Speaker 3: popping Our select shares up seventy eight percent in the
- 1:45Speaker 3: pre market. They're trading at one fourteen, so not too
- 1:47Speaker 3: far off what Gilead has offered. Our Selects is a
- 1:51Speaker 3: biotech company that focuses on immunotherapy patients with cancers, and
- 1:55Speaker 3: Our Selects Gilead already have a collaboration on Our Selection's
- 1:59Speaker 3: lead pipeline candidate. Gilead already owns eleven point five percent
- 2:03Speaker 3: of out standing our Slix's stock, and Gilead has been
- 2:06Speaker 3: looking for deals to supplement its core portfolio, so it's
- 2:09Speaker 3: buying about ninety percent of the other stock that's out.
- 2:12Speaker 3: Big lift in the pre market.
- 2:14Speaker 1: And Mark's making a bit of deal news in sort
- 2:16Speaker 1: of the opposite direction this morning.
- 2:19Speaker 3: That's right, So Mark taker m Marque is up about
- 2:22Speaker 3: one percent in pre market. The company is splitting its
- 2:25Speaker 3: human health business into two units. That's on collegey unit
- 2:28Speaker 3: and then a specialty pharma infectious unit. The company says
- 2:32Speaker 3: that's a response to a more diversified pipeline that it's
- 2:35Speaker 3: pushing out. It currently has eighty phase three studies. The
- 2:38Speaker 3: oncology unit is a beast within Market's contributed over thirty
- 2:43Speaker 3: five of the fifty eight billion dollars in sales last year,
- 2:45Speaker 3: so this is allowing it to focus more on the
- 2:47Speaker 3: encology unit and specially and separate out kind of all
- 2:50Speaker 3: the other drive drivers within that human business. Again, those
- 2:53Speaker 3: shares up about one percent in pre.
- 2:56Speaker 1: And while we wind down earning season, we got some
- 2:58Speaker 1: results this morning from Domino's Pizza Dan.
- 3:01Speaker 2: What did they deliver? Hahaha?
- 3:05Speaker 3: They delivered a beat. So if you if you ordered that,
- 3:08Speaker 3: then congratulations, it's been delivered this morning. Fourth quarter revenue
- 3:12Speaker 3: same store sales growth those both beat estimates. US same
- 3:16Speaker 3: store sales, so that's comparable growth came in at three
- 3:19Speaker 3: point seven percent. That was above estimates. International lag at
- 3:23Speaker 3: zero point seven percent, but enough to drive the revenue beat. However,
- 3:26Speaker 3: the company's margins did shrink, with earnings coming in just
- 3:29Speaker 3: shy of what Wall Street was expecting. Domino cited higher
- 3:33Speaker 3: insurance costs, higher labor rates, and inflation, something we've been
- 3:37Speaker 3: talking about NonStop. Domino's Pizza. Another tailwind is also increasing
- 3:41Speaker 3: its dividend by fifteen percent to nearly two dollars a share,
- 3:44Speaker 3: that was higher than the Bloomberg projection.
- 3:46Speaker 2: This stock Movers report from Bloomberg Radio. Check back with
- 3:51Speaker 2: us throughout the day for the latest roundup of companies
- 3:53Speaker 2: making news on Wall Street and for the latest market
- 3:56Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 4:01Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 4:04Speaker 2: the Bloomberg Business app.